Skip to main content
SpringerLink
Log in

Psychopharmaka und Lebensqualität

  • Chapter
Grundlagen der Neuro-Psychopharmakologie

Zusammenfassung

Verglichen mit einigen anderen Disziplinen der Medizin begann die Lebensqualitäts-Forschung in der Psychiatrie erst spät. Angesichts der Definition von gesundheitsbezogener Lebensqualität als die „vom Patienten selbst berichtete Befindlichkeit und Funktionsfähigkeit in körperlicher, mentaler und sozialer Hinsicht“ (Bullinger und Naber 1999) ist diese Verzögerung erstaunlich. Gerade in der Psychiatrie sind subjektive Befindlichkeit und Funktionsfähigkeit der Patienten als Bestandteile der psychiatrischen Symptoma tik relevant und ihre Verbesserung selbstverständliches Ziel der Therapie. Diese Bereiche mussten somit für die tägliche Arbeit nicht „entdeckt“ werden, wohl aber als Forschungsgegenstand mit der Notwendigkeit einer begriffichen und inhaltlichen Abgrenzung sowie einer methodischen Strukturierung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bandelow B, Stein DJ, Dolberg OT et al. (2007) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40: 152–156

    Article  CAS  PubMed  Google Scholar 

  • Berlim MT, Pargendler J, Brenner J (2007) Significant improvement in the quality of life of Brazilian depressed outpatients 12 weeks following the start of antidepressants. Psychiatry Res 153: 253–259

    Article  CAS  PubMed  Google Scholar 

  • Breier A, Berg P, Thakore J et al. (2005) Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 162: 1879–1887

    Article  PubMed  Google Scholar 

  • Bullinger M (2002) Assessing health related quality of life in medicine. An overview over concepts, methods and applications in international research. Restor Neurol Neurosci 20: 93–101

    PubMed  Google Scholar 

  • Bullinger M, Naber D (1999) Erfassung der Lebens qualität psychisch Kranker. In: Psychiatrie der Gegenwart, Helmchen H, Henn F, Lauter H, Sartorius N (Hrsg.) 4. Auflage, Springer-Verlag Heidelberg, S 235–260

    Google Scholar 

  • Calman KC (1984) Quality of life in cancer patients — an hypothesis. J Med Ethics, 10: 124–127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Demyttenaere K, Fruyt JD, Huygens R (2002) Measuring quality of life in depression. Curr Opinion Psychiatry 15: 89–92

    Article  Google Scholar 

  • Dombrovski AY, Lenze EJ, Dew MA et al. (2007) Maintenance treatment for oldage depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. J Am Geriatr Soc 55: 1325–1332

    Article  PubMed  Google Scholar 

  • Donovan D, Mattson ME, Cisler RA et al. (2005) Quality of life as an outcome measure in alcoholism treatment research. J Stud Alcohol (Suppl.) 119–139

    Google Scholar 

  • Endicott J, Nee J, Harrison W et al. (1993) Quality of Life Enjoyment and Satisfaction Questionnaiere: a new measure. Psychopharmacol Bull 29: 321–326

    CAS  PubMed  Google Scholar 

  • Endicott J, Russell JM, Raskin J et al. (2007) Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry 68: 518–524

    Article  CAS  PubMed  Google Scholar 

  • Foster JH, Powell JE, Marshall EJ et al. (1999) Quality of life on alcohol-dependent subjects: a review. Qual Life Res 8: 255–261

    Article  CAS  PubMed  Google Scholar 

  • Franz M, Meyer T, Reber T et al. (2000) The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients. Qual Life Res 9: 481–489

    Article  CAS  PubMed  Google Scholar 

  • Giacomuzzi S, Riemer Y, Ertl M et al. (2003) Buprenorphine versus methadone maintenance treatment in an ambulant setting: A health-related quality of life assessment. Addiction, 98, 693–702

    Article  CAS  PubMed  Google Scholar 

  • Healy D (1998) Reboxetine, fluoxetine and social functioning as an outcome measure in antidepressant trials: implications. Prim Care Psychiatry 4: 81–89

    Google Scholar 

  • Heinrichs DW, Hanlon TE, Carpenter WT, Jr. (1984) The Quality of Life Scale: an instrument for rating the schizophrenic def cit syndrome. Schizophr Bull 10: 388–398

    Article  CAS  PubMed  Google Scholar 

  • Hunt SM, McKenna SP (1992) The QLDS: a scale for the measurement of quality of life in depression. Health Pol 22: 307–319

    Article  CAS  Google Scholar 

  • Huppert JD, Smith TE (2001) Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. J Nerv Ment Dis 189: 669–75;189: 669–675

    Article  CAS  PubMed  Google Scholar 

  • Jones PB, Barnes TR, Davies L et al. (2006) Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63: 1079–1087

    Article  CAS  PubMed  Google Scholar 

  • Kane JM, Meltzer HY, Carson WH Jr. et al. (2007) Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2: 213–223

    Article  Google Scholar 

  • Karow A, Naber D (2002) Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 162: 3–10

    Article  CAS  PubMed  Google Scholar 

  • Karow A, Moritz S, Lambert M et al. (2005) PANSS syndromes and quality of life in schizophrenia. Psychopathology 38: 320–326

    Article  CAS  PubMed  Google Scholar 

  • Katschnig H, Angermeyer MC, Katschnig H et al. (1997) Quality of Life in Depression. In, Quality of Life in Mental Disorders. Chicester: Wiley J. 3–17

    Google Scholar 

  • Kennedy S, Eisfeld B, Cooke R (2001) Quality of life: an important dimension in assessing the treatment of depression? J Psychiatry Neurosci 26: 23–28

    Google Scholar 

  • Laaksonen E, Koski-Jännes A, Salaspuro M et al. (2008) A randomized, multi-centre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 43: 53–61

    Article  CAS  PubMed  Google Scholar 

  • Lambert M, Naber D (2004) Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18: 5–17

    Article  PubMed  Google Scholar 

  • Lewis W, Barnes T, Davies L et al. (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32: 715–723

    Article  PubMed  PubMed Central  Google Scholar 

  • Llorca P, Fernandez J (2007) Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 61: 702–710

    Article  CAS  PubMed  Google Scholar 

  • Maremmani I, Pani P, Pacini M (2007) Substance use and quality of life over 12 month among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Sub Abuse Treatment 33: 91–98

    Article  Google Scholar 

  • Meltzer HY, Burnett S, Bastiani B et al. (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 41: 892–897

    CAS  Google Scholar 

  • Mortimer AM, Agib AO (2007) Quality of Life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative crosssectional study. Int J Soc Psychiatry 53: 99–107

    Article  PubMed  Google Scholar 

  • Moses T, Leuchter A, Cook I (2006) Does the cinical course of depression determine improvement in symptoms and quality of life?. J Nerv Ment Dis 194: 241–248

    Article  PubMed  Google Scholar 

  • Naber D, Riedel M, Klimke A et al. (2005) Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 111: 106–115

    Article  CAS  PubMed  Google Scholar 

  • Naber D, Moritz S, Lambert M et al. (2001) Improvement of schizophrenic patients subjective well-being under atypical antipsychotic drugs. Schizoprenia Research 50: 79–88

    Article  CAS  Google Scholar 

  • Narvaez JM, Twamley EW, McKibbin CL et al. (2008) Subjective and objective quality of life in schizophrenia. Schizophrenia Research 98: 201–208

    Article  PubMed  Google Scholar 

  • Perneger TV, Giner F, del Rio M, Mino (1998) A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 317: 13–18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Phillips GA, van Brunt DL, Roychowdhury SM et al. (2006) The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry 67: 1397–1403

    Article  PubMed  Google Scholar 

  • Pollack MH, Lepola U, Koponen H et al. (2007) A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24: 1–14.

    Article  CAS  PubMed  Google Scholar 

  • Ponizovsky AM, Grinshpoon A. (2007) Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse 33: 631–642

    Article  PubMed  Google Scholar 

  • Pukrop R (2006) For and against: is quality of life a meaningful indicator of outcome? Against. Psychiatrische Praxis 33: 314–316

    PubMed  Google Scholar 

  • Rapaport MH, Clary C, Fayyad R (2005) Quality of life impairment in depressive and anxiety disorders. Am J Psychiatry 162: 1171–1178

    Article  PubMed  Google Scholar 

  • Ritsner M, Perelroyzen G, Ilan H et al. (2004) Subjective response to antipsychotics of schizophrenia patients treaed in routine clinical practice. A naturalistic comparative study. J Clin Psychopharmacol 24: 245–254

    Article  PubMed  Google Scholar 

  • Shelton RC, Haman KL, Rapaport MH et al. (2006) A randomized, double-blind, active-control study of sert raline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 67: 1674–1681

    Article  CAS  PubMed  Google Scholar 

  • Skevington SM, Wright A (2001) Changes in the quality of life patients receiving antidepressant medication in primary care: validation of the WHO-QOL-100. Br J Psychiatry 178: 261–267

    Article  CAS  PubMed  Google Scholar 

  • Souêtre E, Martin P, Lozet H et al. (1996) Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol 11: 45–52

    Article  PubMed  Google Scholar 

  • Swartz M, Perkins D, Stroup T et al. (2007) Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. Am J Psychiatry 164: 428–436

    Article  PubMed  Google Scholar 

  • Torrens M, Domingo-Salvany A, Alonso J et al. (1999) Methadone and quality of life. Lancet 353: 1101 Lancet

    Article  CAS  PubMed  Google Scholar 

  • Voruganti L, Cortese L, Oyewumi L et al. (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43: 135–145

    Article  CAS  PubMed  Google Scholar 

  • Voruganti LP, Awad AG, Parker G et al. (2007) Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 96: 146–155

    Article  CAS  PubMed  Google Scholar 

  • Wehmeier P, Kluge M, Schacht A et al. (2007) Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res 91: 178–186

    Article  PubMed  Google Scholar 

  • WHOQOL Group (1998) The World Health Organization Quality of Life Assessment (WHOQOL): Development and Psychometric properties. Soc Science Med 46: 1569–1585

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    Prof. Dr. med. Dieter Naber, Prof. Dr. Monika Bullinger & Dr. Anne Karow

Authors
  1. Prof. Dr. med. Dieter Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Monika Bullinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. Anne Karow
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Klinische Neurochemie, Universität Würzburg, Deutschland

    Peter Franz Riederer

  2. Inn-Salzach-Klinikum gGmbH, Fachkrankenhaus für Psychiatrie, Psychotherapie, Psychosomatische Medizin und Neurologie, Wasserburg a. Inn · Rosenheim · Freilassing, Akademisches Lehrkrankenhaus der Ludwig-Maximilians-Universität München, Deutschland

    Gerd Laux

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag/Wien

About this chapter

Cite this chapter

Naber, D., Bullinger, M., Karow, A. (2010). Psychopharmaka und Lebensqualität. In: Riederer, P.F., Laux, G. (eds) Grundlagen der Neuro-Psychopharmakologie. Springer, Vienna. https://doi.org/10.1007/978-3-211-85473-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-85473-0_13

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-85472-3

  • Online ISBN: 978-3-211-85473-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation